구글 검색

검색어: pilotpētījums (라트비아어 - 영어)

인적 기여

전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.

번역 추가

라트비아어

영어

정보

라트비아어

pilotpētījums N ar PR = 11

영어

Single Centre Pilot Trial N with CR = 11

마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:

라트비아어

Viena centra pilotpētījums N ar CR = 11

영어

Single Centre Pilot Trial N with CR = 11

마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:

라트비아어

Pilotpētījums par atlieku samazināšanos ar cūkām tika veikts, lai noskaidrotu laika periodus, kuros veikt galveno pētījumu par atlieku izzušanu.

영어

The pilot residue depletion study in pigs was performed to identify the time points to be used in the pivotal residue depletion study.

마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:

라트비아어

Veicot mijiedarbības pilotpētījumu 7 pacientiem ar PAH, kas lietoja stabilu sildenafila devu (20 mg trīs reizes dienā), vienreizēju riociguata devu nozīmēšana (secīga 0,5 mg un 1 mg lietošana) izraisīja papildu hemodinamisko iedarbību.

영어

In an exploratory interaction study in 7 patients with PAH on stable sildenafil treatment (20 mg three times daily) single doses of riociguat (0.5 mg and 1 mg sequentially) showed additive haemodynamic effects.

마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:

라트비아어

Kopā 18 pacienti ar ADA-SCID tika ārstēti ar Strimvelis viena atklāta, pivotāla pētījuma (AD1115611; N=12), divu agrīnu, atklātu pilotpētījumu (AD1117054/AD1117056; N=3) un līdzcietīgas zāļu lietošanas programmas (AD1117064; N=3) ietvaros.

영어

A total of 18 patients with ADA-SCID were treated with Strimvelis as part of one open-label pivotal trial (AD1115611; N=12), two early open-label pilot studies (AD1117054/AD1117056; N=3), and a compassionate use program (AD1117064; N=3).

마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:

라트비아어

Pediatriskie pacienti: par celekoksiba lietošanu līdz 18 gadus veciem FAP pacientiem pieejams tikai viens neliels pilotpētījums ar ļoti mazu populāciju, kurā pacientus ārstēja ar celekoksiba devām līdz 16 mg /kg ķermeņa masas dienā, kas atbilst pieaugušajiem ieteiktajai FAP devai 800 mg dienā (skatīt apakšpunktu 5.1).

영어

Paediatric patients: Experience with celecoxib in FAP patients below the age of 18 years is limited to a single pilot study in a very small population, in which patients were treated with celecoxib at doses up to 16 mg/kg daily, which corresponds to the recommended adult FAP dose of 800 mg daily (see section 5.1).

마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:

라트비아어

Pilotpētījums ar bērniem, FAP pacientiem: kopumā 18 bērni vecumā no 10 līdz 14 gadiem, kuriem bija genotipa vai fenotipa pozitīva FAP tika ārstēti ar celekoksibu 4 mg/kg dienā (4 pacienti salīdzinājumā ar 2 pacientiem, kas saņēma placebo) vai ar celekoksibu 8 mg/kg dienā (4 pacienti salīdzinājumā ar 2 pacientiem, kas saņēma placebo), vai ar celekoksibu 16 mg/kg dienā (4 pacienti salīdzinājumā ar 2 pacientiem, kas saņēma placebo).

영어

Pilot Study in Juvenile FAP Patients: A total of 18 children 10 to 14 years of age who had genotype or phenotype positive FAP were treated with celecoxib 4 mg/kg/day (4 patients, compared to 2 patients treated with placebo), celecoxib 8 mg/kg/day (4 patients, compared to 2 patients treated with placebo), or celecoxib 16 mg/kg/day (4 patients, compared to 2 patients treated with placebo).

마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:

라트비아어

Pilotpētījumā ir konstatēts, ka zidovudīns ir inkorporēts leikocītu nukleārajā DNS pieaugušajiem, ieskaitot grūtnieces, kuras lieto zidovudīnu HIV-1 infekcijas ārstēšanai vai vīrusu transmisijas profilaksei no mātes uz bērnu.

영어

A pilot study has demonstrated that zidovudine is incorporated into leukocyte nuclear DNA of adults, including pregnant women, taking zidovudine as treatment for HIV-1 infection, or for the prevention of mother to child viral transmission.

마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:

라트비아어

Šī pilotpētījuma rezultāti tika izmantoti, lai plānotu un realizētu 3. fāzes pētījumu, kurā piedalījās vairākas valstis.

영어

Results of this pilot study were used to design and implement a multi-national phase 3 trial.

마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:

라트비아어

Vienai pētāmajai personai, kas tika ārstēta pilotpētījumā, nebija datu par PEG-ADA atkārtotu ievadīšanu, tāpēc tā netika iekļauta neiejaukšanās dzīvildzes integrētajā populācijā.

영어

One subject treated in a pilot study did not have PEG-ADA re-introduction data, and thus was excluded from the intervention-free survival in the integrated population.

마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:

라트비아어

Divu 12-mēnešu ilgu multicentrālu pilotpētījumu (piedaloties kopumā 722 pacientiem) rezultātā, salīdzinot baziliksimabu ar placebo, novērots, ka baziliksimabs, lietojot vienlaicīgi ar ciklosporīnu mikroemulsijā un kortikosteroīdiem, būtiski samazināja akūtu atgrūšanas epizožu biežumu vienā gadījumā 6 mēnešu laikā (31% vs.

영어

Results from two pivotal 12-month multicentre studies (722 patients in total) comparing basiliximab with placebo show that basiliximab, used concomitantly with ciclosporin for microemulsion and corticosteroids, significantly reduces the incidence of acute rejection episodes both within 6 (31% vs.

마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:

라트비아어

Pilotpētījumā ir konstatēts, ka zidovudīns ir inkorporēts leikocītu nukleārajā DNS pieaugušajiem, ieskaitot grūtnieces, kas lieto zidovudīnu HIV-1 infekcijas ārstēšanai vai vīrusu transmisijas profilaksei no mātes uz bērnu.

영어

A pilot study has demonstrated that zidovudine is incorporated into leukocyte nuclear DNA of adults, including pregnant women, taking zidovudine as treatment for HIV-1 infection, or for the prevention of mother to child viral transmission.

마지막 업데이트: 2017-04-26
사용 빈도: 5
품질:

라트비아어

2004. gadā tiks atbalstīta virkne pilotpētījumu par konkrētu Kopienas pasākumu un iniciatīvu (to skaitā arī garīgā veselība) ietekmi uz veselību, uzsverot arī pieredzi, kas gūta pētījumu veikšanas laikā.

영어

A series of pilot studies on the health impact of particular Community actions and initiatives (including mental health), stressing also lessons learnt in the process of conducting the studies, will be supported in 2004.

마지막 업데이트: 2014-11-21
사용 빈도: 1
품질:

라트비아어

Pediatriskie pacienti: par celekoksiba lietošanu līdz 18 gadus veciem FAP pacientiem pieejams tikai viens neliels pilotpētījums ar ļoti mazu populāciju, kurā pacientus ārstēja ar celekoksiba devām līdz 16 mg/ kg ķermeņa masas dienā, kas atbilst pieaugušajiem ieteiktajai FAP devai 800 mg dienā (skatīt apakšpunktu 5. 1).

영어

Experience with celecoxib in FAP patients below the age of 18 years is limited to a single pilot study in a very small population, in which patients were treated with celecoxib at doses up to 16 mg/ kg daily, which corresponds to the recommended adult FAP dose of 800 mg daily (see section 5.1).

마지막 업데이트: 2012-04-10
사용 빈도: 4
품질:

라트비아어

Veterināro zāļu komiteja (CVMP) ir novērtējusi pilotpētījumu, galveno eksperimentālo pētījumu, 2 praktisku izmēģinājumu pārskata ziņojumus, kā arī citus reģistrācijas apliecības īpašnieka iesniegtos datus par iedarbīgumu, farmakokinētiskajām īpašībām un toleranci.

영어

The CVMP has assessed a pilot study, a main experimental study, 2 field trial reports as well as other efficacy, pharmacokinetics and tolerance data submitted by the marketing authorisation holder.

마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:

인적 기여로
4,401,923,520 더 나은 번역을 얻을 수 있습니다

사용자가 도움을 필요로 합니다:



당사는 사용자 경험을 향상시키기 위해 쿠키를 사용합니다. 귀하께서 본 사이트를 계속 방문하시는 것은 당사의 쿠키 사용에 동의하시는 것으로 간주됩니다. 자세히 보기. 확인